ZURICH (Reuters) – Swiss drugmaker Roche has ended efforts to develop a heart disease drug that according to some industry analysts could have achieved $ 10 billion annual sales, after poor results from a late stage trial.
- Prenatal drug targeted lesbians, researchers say
- FDA approves Protalix’s Gaucher drug Elelyso
- HEART DISEASE AWARENESS MILLION DOLLAR NOVELTY BILL – Lot of 10 BILLS
- Novartis drug Afinitor wins EU nod to treat breast cancer
- Drug shortages down, but some linger longer